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RESUMO 
À perturbação metabólica provocada pela incapacidade ou pela diminuição da 
capacidade de produção de insulina no pâncreas, designamos comummente por 
Diabetes. Esta patologia de aparente simples definição, é de facto um processo bastante 
complexo e de difícil controlo, será talvez por tal facto que actualmente a apelidamos de 
“Epidemia do Mundo Moderno”. Não obstante à medida que esta patologia progride e 
se adensa a severidade da sintomatologia associada aumenta proporcionalmente, 
estando inerente um maior risco de complicações quer microvasculares, tais como 
retinopatia, nefropatia, neuropatia como macrovasculares. Consequentemente, as 
diabetes induzem alterações fisiológicas e metabólicas na retina nas quais a inflamação 
parece desempenhar um importante papel, em particular no desenvolvimento da 
retinopatia diabética. Neste contexto o presente estudo pretendeu aferir a putativa 
capacidade de um antidiabético, inibidor da DPP-IV, – Sitagliptina – de aliviar ou mesmo 
reverter esta sintomatologia microvascular. Posto isto, células endoteliais da retina de 
bovino - BREC – foram em concomitância tratadas durante 6 horas com duas 
concentrações de uma citocina pró-inflamatória – TNF – e de Sitagliptina, 
respectivamente, 5 ng/ml e 10 ng/ml ou 100 nM e 100 µM. Seguidamente, a formação 
de estruturas semelhantes a tubos, migração e proliferação de células endoteliais foram 
avaliadas, tendo tais funções sido preservadas ou, quando diminuídas devido ao TNF, 
reestabelecidas pela Sitagliptina. Em suma, resultados preliminares obtidos sugerem que 
a Sitagliptina exerce efeitos citoprotectores na microvasculatura da retina, quando 
instalada uma condição inflamatória, o que é indicativo dos benefícios anti-inflamatórios 
deste inibidor da DPP-IV na retina. No entanto, estudos adicionais são necessários tanto 
para confirmar estes resultados como para entender melhor os adjacentes mecanismos 
celulares e moleculares envolvidos neste efeito protector mediado pela Sitagliptina. Por 
conseguinte, tais dados podem contribuir para o desenvolvimento de novas e mais 
eficazes estratégias terapêuticas dirigidas para a prevenção ou centradas na 
minimização dos efeitos nefastos induzidos pela hiperglicemia crónica na 
microvasculatura da retina. Assim, um conhecimento mais aprofundado e detalhado 
destes inibidores da DPP-IV irão contribuir para um prognóstico mais aferido e eficaz e 
quiçá a almejada cura completa da Diabetes. 
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ABSTRACT 
Diabetes is essentially a metabolic disruption caused either by the inability or by 
the decrease in pancreas insulin’s production capacity. On the other hand this 
apparently, in-a-few-words simple definition is in fact a process that could be as complex 
as hard to control. More importantly, it might be considered as the “Modern World 
Epidemic” becoming more severe as it extends and progresses. Thus the association 
between intensity and the overall duration of hyperglycemia periods increases the risk 
of microvascular complications such as, retinopathy, nephropathy, neuropathy and 
macrovascular ones. More so, Diabetes induces metabolic and physiological 
abnormalities in the retina in which inflammation seems to play a major role particularly 
in the development of diabetic retinopathy. In this context, the aim of this study was to 
verify if an antidiabetic DPP-IV inhibitor, Sitagliptin, could alleviate some of these 
symptoms. Therefore bovine retinal endothelial cells – BREC - where co-treated with 
two concentrations of an inflammatory cytokine TNF and Sitagliptin, respectively 5 
ng/ml and 10 ng/ml or 100 nM and 100 µM for 6 hours. EC tube-like structures 
formation, migration and proliferation abilities seem as a result to be conserved by 
Sitagliptin and when impaired due to TNF reestablished by the first. In conclusion 
preliminary results obtained suggest that Sitagliptin exerts cytoprotective effects to the 
microvasculature of the retina, when an inflammatory condition is settled. What 
indicates that this DPP-IV inhibitor can have anti-inflammatory benefits to the retina. 
However additional studies are mandatory to both confirm these results and to further 
understand the underlined molecular and cellular mechanisms involved in this 
Sitagliptin-mediated-protective-action. This may contribute to the development of new 
and more effective therapeutic strategies directed to the prevention or focused in the 
minimization of the damaging-hyperglycemia-induced effects in the retina’s 
microvasculature. Nevertheless obtaining clear information about these mechanisms 
could contribute to an elevated knowledge, thorough diagnosis and in general putative 
cure for diabetes. 
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1. DIABETES MELLITUS 
1.1. BRIEF STORY ABOUT DIABETES HISTORY 
An Egyptian manuscript from c. 1500 BCE mentioning "passing of too much 
urine" is thought to be one of the first diseases description. In addition the first cases 
reported are believed to be of type 1 diabetes. Around the same time, Indian physicians 
noting the urine would attract ants, also identified the disease and classified it as 
madhumeha or "honey urine". 
The term "diabetes" or "to pass through" was only used in 230 BCE by the 
Greek Appollonius of Memphis. During the Roman Empire the disease was considered 
rare with Galen commenting he had only seen two cases during his entire career. 
(DiabeWorld, 2012) This is possibly due to ancient people dieting and life-style, or even 
because clinical symptoms were only observed during a more advanced stage of the 
disease, Galen named the disease "diarrhea of the urine" (diarrhea urinosa) 
(MiYDiabetes, 2012). 
The earliest surviving work with a detailed reference to diabetes is that of 
Aretaeus of Cappadocia, reflecting the beliefs of the "Pneumatic School" he described 
the symptoms and the disease course, which he attributed to the moisture and 
coldness. He hypothesized a correlation of diabetes with other diseases, discussing 
differential diagnosis from the snakebite which also provokes excessive thirst. His work 
remained unknown until middle of the 16th century when, in 1552, the first Latin edition 
was published in Venice (Diabetes India, 2012). 
Moreover type 1 and type 2 diabetes where identified as separate conditions 
for the first time by the Indian physicians Sushruta and Charaka in 400-500 CE with type 
1 associated with youth and type 2 with being overweight. 
The term "mellitus" or "from honey" however was added by the Briton John 
Rolle in the late 1700s, when he noticed the urine of a diabetic had a sweet taste 
(glycosuria) and to separate the condition from diabetes insipidus, which is also 
associated with frequent urination. When Canadians Frederick Banting and Charles 
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Herbert Best isolated and purified insulin, in 1921 and 1922, the effective treatment was 
developed. This important finding was followed by the development of the long-acting 
insulin NPH in the 1940s. (Ahmed A.M. et al., 2002) 
1.2. DEFINITION AND CHARACTERIZATION 
Diabetes Mellitus was considered by the World Health Organization (WHO) as a 
complex and heterogeneous metabolic disorder, which is characterized through a 
chronic hyperglycemia with atypical carbohydrates, lipids and proteins metabolism, 
leading to insulin secretion and/or insulin action deficiency (WHO, 2012).This pathology 
may present characteristic symptoms such as thirst, polyuria, blurring of vision, and 
weight loss. In its most severe forms, ketoacidosis or a non-ketotic hyperosmolar state 
may develop and lead to stupor, coma and, in absence of effective treatment, death. 
(WHO, 2012, IDF, 2012)) 
Moreover the pathogenetic processes involved in the development of diabetes 
include pancreatic beta cells destruction with consequent insulin deficiency, and others 
that result in resistance to insulin action (Eizirik et al., 2008). This leads to the 
progressive development of specific complications, namely retinopathy with potential 
blindness, nephropathy that may lead to renal failure, and/or neuropathy with risk of 
foot ulcers, amputation and Charcot joints. People with diabetes are also at increased 
risk of cardiovascular, peripheral vascular and cerebrovascular disease (IDF, 2012, 
Medical News Today, 2012) 
1.3. PREVALENCE 
Worldwide, we have been assisting to an increase in Diabetes prevalence which 
is inevitably overwhelming to our already overburdened health system. Hence type 2 
Diabetes is the one to be blamed when it comes to this escalating aggravation, not only 
due to ever growing world population but also the continuously aging demography. 
Nevertheless a massive increase in overweight and obese people due to sedentary and 
overall lack of a healthy life style, might as well contribute to a bigger risk of suffering 
from this disease (Zimmet et al., 2001) 
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Diabetes Mellitus prevalence rates have critically risen in recent years and in 
accordance to the International Diabetes Federation (IDF), Diabetes Mellitus is 
frequently a non-communicable disease, with high morbidity and mortality rates, just in 
2012 alone were registered about 4.8 million casualties. (IDF, 2012) 
In the present, Diabetes affects about 371 million people (Figure 1.1) and with 
an estimated increase to 552 million by 2030, thus representing 8.3% of adult 
population. However, these numbers are underestimated due to the undiagnosed 
patients, who represent almost half the people with Diabetes (IDF, 2012). Regarding 
Portugal, the Sociedade Portuguesa de Diabetologia (Portuguese Diabetes Society) 
estimates that 12.7% of the Portuguese adult population will be diabetic, from which 
5.4% might still remain undiagnosed (SPD, 2012). 
 
 
 
 
 
1.4. MOST COMMON TYPES 
In accordance to WHO and IDF there are three main types of diabetes, namely: 
type 1 diabetes mellitus (T1DM) also called insulin-dependent, type 2 diabetes mellitus 
(T2DM) known as insulin-resistance and gestational diabetes 
  
Figure 1.1 - Global prevalence (%) of diabetes mellitus in adult population (20-79 years) in 2012, shown by 
geographic region (Image taken from IDF Diabetes Atlas, 5th Edition (IDF, 2012) 
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1.4.1. TYPE 1 DIABETES MELLITUS 
Type 1 diabetes also called as insulin-dependent diabetes, or juvenile-onset 
diabetes, is characterized by the presence of anti-GAD, islet cell or insulin antibodies 
which identify the autoimmune processes that mediate the destruction of pancreatic 
beta cells. Albeit these patients not being necessarily obese they may instead have other 
autoimmune disorders such as Graves' disease, Hashimoto's thyroiditis, and Addison's 
disease (Betterle et al., 1983). 
The first manifestation in some 
patients, particularly in children might be 
ketoacidosis or modest fasting 
hyperglycaemia. A few adults however may 
retain residual beta-cell function, sufficient to 
prevent ketoacidosis, for many years (Japan 
and Pittsburgh Childhood Diabetes Research 
Groups, 1985). Eventually, individuals with this 
form of Type 1 diabetes often become 
dependent on insulin for survival in order to 
prevent the development of ketoacidosis 
(Zimmet et al.,1995, Willis et al., 1996).  At 
this stage of the disease, there is little or no insulin secretion (Figure 1.2) as manifested 
by low or undetectable levels of plasma C-peptide (Hother et al., 1988) There is however 
both a genetic predisposition to autoimmune destruction of beta cells as a relation 
between environmental factors, which remains yet known.  
1.4.2. TYPE 2 DIABETES MELLITUS 
Type 2 diabetes previously encompassed non-insulin dependent diabetes or 
adult-onset diabetes, and accounts for at least 90% of all cases of diabetes. It is 
characterised by insulin resistance and relative insulin deficiency (Figure 1.3), either or 
both of which may be present at the time diabetes is diagnosed. 
Figure 1.2 - Carrier proteins involved in type 1 
Diabetes (Diabetes Education Online, 2012) 
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Type 2 diabetes risk increases with 
age, hypertension, dyslipidaemia and overall 
lack of physical activity (Zimmet et al., 1992, 
Harris et al., 1995). It might be probably 
associated with strong familial, likely genetic, 
predisposition (Valle et al., 1997, Knowler et 
al., 1993). Despite the genetics of this 
diabetic form it is still rather complex and not 
clearly defined. 
It is often, but not always, 
associated with overweight, obesity or even 
predominantly body fat in the abdominal areas, which itself can cause insulin resistance 
and lead to high blood glucose levels. People with type 2 diabetes can often initially 
manage their condition through exercise and diet. However, over time most people will 
require oral drugs and or insulin (Kissebah et al., 1982).  
2. DIABETIC RETINOPATHY 
2.1. DEFINITION AND CHARACTERIZATION 
Diabetic Retinopathy (DR) is a 
microvascular complication of diabetes 
(Aielo et al., 1998, Davidson et al., 2007), in 
early stages of the disease are characterized 
by vascular alterations in blood flow, death 
of retinal pericytes (perivascular contractile 
cells), basement membrane thickening and 
subtle increases in vascular 
permeability.(Aveleira et al., 2010, Zhang et 
al., 2011, Sheetz et al., 2002) As the disease progresses, clear alterations in the vascular 
structure, for instance non-perfused vessels, microaneurysms, dot/blot hemorrhages, 
Figure 1.3 – Carrier proteins involved in type 
12Diabetes (Diabetes Education Online, 2012) 
Figure 1.4 - Normal eye anatomy (National Eye 
Institute, 2012) 
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cotton-wool spots, venous beading, vascular loops and significant vascular leakage can 
be seen under ophthalmologic examination (Cockburn et al., 1999). 
2.2. DR PROGRESSION 
The vascular changes stated above occur in an early phase – the non-
proliferative stage – of DR, where, as a consequence of increased vascular permeability, 
the macular edema formed can eventually lead to vision loss. Later on, in the 
proliferative stage of DR, neovascularization takes place on the retinal surface, after that 
vascular function becomes impaired by capillary occlusion, non-perfusion and 
degeneration. In this stage, severe vision loss or even blindness may as well be caused 
by bleeding, hemorrhage and subsequent retinal detachment due to the newly formed 
but rather fragile vessels (Davidson et al., 2007). 
Diabetic retinopathy progression can be identified into four stages, which were 
conveniently enumerated down below: 
I. Mild Nonproliferative Retinopathy: At this earliest stage, microaneurysms 
occur. They are small areas of balloon-like swelling in the retina's tiny blood vessels. 
II. Moderate Nonproliferative Retinopathy: As the disease progresses, some 
blood vessels that nourish the retina are blocked. 
III. Severe Nonproliferative Retinopathy: Many more blood vessels are 
blocked, depriving several areas of the retina with their blood supply. These areas of the 
retina send signals to the body to grow new blood vessels for nourishment 
IV. Proliferative Retinopathy: At this advanced stage, the signals sent by the 
retina for nourishment trigger the growth of new blood vessels. This condition is called 
proliferative retinopathy. These new blood vessels are abnormal and fragile. They grow 
along the retina and along the surface of the clear, vitreous gel that fills the inside of the 
eye.  
The mechanisms by which diabetes causes microvascular complications and 
disease progression in the retina are not yet fully understood. However, further studies 
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in patient samples and animal models have shown that DR could be definitely 
characterized as a chronic, hence subclinical inflammation. 
 
 
 
2.3. MAJOR PATHOGENIC PATHWAYS IN DIABETIC RETINOPATHY 
The increase in polyol pathway, non-enzymatic glycosylation of proteins, 
oxidative stress and protein-c kinase activation by generation of diacylglycerol, are 
retinal biochemical and cellular abnormalities induced by chronic hyperglycemia that 
lead to vascular impairments. Albeit this, the true mechanism behind hyperglycemia-
induced-DR remains yet known. 
2.3.1. POLYOL PATHWAY 
Glucose uptake by retinal tissue is insulin-independent existing therefore an 
equilibrium between retinal and plasmatic glucose levels. When hyperglycemia is 
present it activates the polyol pathway, converting, through aldose reductase, glucose in 
sorbitol and then in fructose (by sorbitol dehydrogenase) (Miwa et al., 2003) 
Subsequently, in the retina, the intracellular increase in sorbitol concentration 
causes osmotic breakdown, damages retinal pericytes, via apoptosis, and thickens 
retinal vascular endothelial cell basement membranes leading to closure of retinal 
capillaries. These changes in membrane permeability and integrity have been identified 
as the key to early cellular pathology (Lorenzi et al., 2007). 
 
Figure 1.5 - Normal Vision and the same scene viewed by a person with Diabetic Retinopathy (National Eye 
Institute, 2012) 
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2.3.2. AGES PATHWAY 
The hyperglycemia also leads to lipid and protein glycosylation, whose 
oxidation produces glycotoxins and Advanced Glicosilated End-products (AGEs) 
(Schleicher et al., 1997). These AGEs can be correlated with Diabetes duration and 
severity, being found in the plasma, tissue and vessels walls, exerting their action 
through endothelium-expressed receptors, promoting an increase in vascular 
permeability and thrombogenicity (Kowluru and Odenbach et al., 2004, Libby et al., 
2007). Nevertheless numerous are the mechanism that control vascular tonicity, that 
when Diabetes-activated can lead to vascular hemodynamic regulation loss. 
2.3.3. OXIDATIVE STRESS 
There is evidence that oxidative stress, defined as a persistent imbalance 
between the production of highly reactive molecular species (chiefly oxygen and 
nitrogen) and antioxidant defenses, can lead to tissue damage (Rosen et al., 2001). 
Oxidative stress results from increased content of reactive oxygen species (ROS) and/or 
reactive nitrogen species (RNS). Examples of ROS include charged species such as 
superoxide(O2
- •) and the hydroxyl radical (OH•), and uncharged species such as 
hydrogen peroxide (Rosen et al., 2001, Irani et al, 2000). There are also data indicating 
that ROS formation is a direct consequence of hyperglycemia (Brownlee et al., 2001); 
more recent studies have suggested that increased free fatty acids levels may also result 
in ROS formation. 
Because of their ability to directly oxidize and damage DNA, protein, and lipid, 
ROS are believed to play a key direct role in the pathogenesis of late diabetic 
complications (Rosen et al., 2001, Nishikawa et al., 2000). In addition, ROS can function 
as signaling molecules to activate a number of cellular stress-sensitive pathways that 
cause cellular damage, and are ultimately responsible for the late complications of 
diabetes. Furthermore, these same pathways are linked to insulin resistance and 
decreased insulin secretion (Wolff et al., 1991). 
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2.3.4. PROTEIN KINASE C PATHWAY 
Studies indicate that enhanced generation of diacylglycerol – a physiologic 
activator of PKC – , hence a PKC pathway activation might play a major role in 
hyperglycaemia-induced microvascular dysfunction in diabetes by promoting increased 
flux through the polyol pathway (Keogh et al., 1997) and the generation of AGEs (Portilla 
et al., 2000) and oxidative species result in. 
PKC which functions as signaling components for a variety of growth factors, 
hormones, neurotransmitters and cytokines, when activated results in numerous 
cellular changes, leading to basement membrane thickening and increased production 
of vasodilatory prostaglandins as well as vascular endothelial growth factor (VEGF), 
which in turn affect vessel permeability and/or blood flow, leading to vascular 
impairment (Koya and King et al., 1998, Das Evcimen and King et al.,2007). 
3. INFLAMMATION 
The role of inflammation in the development and progression of diabetic 
retinopathy has been studied for a long time but it was in the last years that it started to 
get some major attention. Powell and Field in 1960 observed that diabetics treated with 
anti-inflammatory agents like “salicylate” had a lower incidence rate of diabetic 
retinopathy (Powell et al., 1964). Earlier studies by Lutty and his group identified the 
important role of leukocytes in the development of diabetic retinopathy (Lutty et al., 
1997, McLeod et al., 1995) and a subsequent study has established diabetic retinopathy 
as an “inflammatory disease” (Adamis et al., 2002). 
This inflammatory state starts very early within one week of experimental 
diabetes, due to leukocytes accumulation in the vasculature of the retina (Adamis et al., 
2002). Widely observed in diabetic retinopathy the major components of the 
inflammatory phenotype progress towards the increase in diabetic macular edema 
(retinal vascular permeability) and neovascularization (proliferative diabetic retinopathy) 
(Table 1.6). 
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Increased Expression of Inflammatory Adhesion Molecules ICAM-1 
and VCAM-1 in the Endothelium 
Adhesion Leukocytes to Retinal vessels 
Increased Expression of Cytokines and Growth factors 
Microglial Cell Activation 
Infiltration of Monocytes and Neutrophils 
Increased Vascular permeability (Macular Edema) and 
Neovascularization (Proliferative Retinopathy) 
Retinal Cell Death 
Table 1.6 - Components of Diabetic Retinal Inflammation (Adapted from Antonetti et al., 2006 and Adamis et 
al.,2002) 
3.1. INFLAMMATORY BIOMARKERS IN DIABETIC RETINOPATHY 
The main risk factors for diabetic retinopathy include diabetes duration, 
hyperglycemia, hypertension, and dyslipidemia, which only can explain some degree of 
variance in the risk of diabetic retinopathy (Nguyen et al., 2009). Studies have therefore 
shown the association of multiple systemic inflammatory factors in the progression of 
diabetic retinopathy, and a further analysis of diabetic vitreous samples has also 
provided insights into novel proinflammatory markers in this process (Schmidt et al., 
1995, Schram et al., 2003). 
Furthermore inflammation is a complex biological response of vascular tissues 
against harmful stimuli, including damaged cells, irritants, or pathogens being also a 
critical step in wound healing (Wagener et al., 2013). This process involves multiple 
mediators such as pro-inflammatory cytokines, chemokines and adhesion molecules that 
initiate the interaction between leukocytes and the endothelium, guiding directional 
leukocyte migration toward infected or injured tissue (Zhang et al., 2011). 
First, the pro-inflammatory cytokines (such as tumor necrosis factor (TNF) and 
interleukins) and the chemokines (such as CCL2 and CCL5) released from 
infected/injured tissue, activate the endothelium to increase expression of adhesion 
molecules (such as E-selectin, intercellular adhesion molecule (ICAM)-1, vascular cell 
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adhesion molecule (VCAM)-1) and chemokines (Zhang et al., 2011). Then leukocytes, 
mediated by chemokines and adhesion molecules, attach to the vessel wall, 
transmigrate through the endothelium and linger in the infected or injured tissue until 
complete healing (Barreiro et al., 2010). While normal inflammation is beneficial, 
excessive or uncontrolled one, like the one seen in DR, can cause tissue injury and 
ultimately result in diseases (Barreiro et al., 2010). 
Although there are no known pathogens in DR, analysis of inflammatory 
molecules in vitreous, serum and retina form diabetic patients or experimental animals 
indicate that DR is associated with significant increases in pro-inflammatory cytokines, 
chemokines and adhesion molecules (Zhang et al., 2011). High levels of interleukin-1β 
(IL-1β) and caspase 1 – its downstream signaling molecule – as well as TNF are 
significantly increased in vitreous, retinas and serum from diabetic patients and rats 
(Demircan et al., 2006, Vincent et al., 2007, Kowluru et al., 2004). Nevertheless TNF also 
appears to be augmented in ocular fibrovascular membranes from patients with DR and 
in retinas from rodent model of diabetes mellitus (Joussen et al., 2006, Limb et al., 
1996). 
On the other hand, vitreous samples from DR patients also show that certain 
chemokines such as CCL2, 
CCL5, CXCL8, CXCL10 and 
CXCL12 are also upregulated 
(Murugeswari et al., 2008, 
Meleth et al., 2005). 
Furthermore, Increases in IL-6, 
ICAM-1 and VCAM-1 have 
been shown to be related to 
the progression of DR (Meleth 
et al., 2005, Adamiec-
Mroczek, 2008) (Figure 1.7). 
 
Figure 1.7 - Inflammatory pathway in Diabetic Retinopathy (Medscape 
2011) 
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This correlation between increases in inflammatory molecules can also be 
associated with recruitment of leukocytes, for example the quantity of neutrophils is 
significantly elevated in both retinal and choroidal vessels from diabetic patients and 
rhesus monkeys (Kim et al., 2005). Whereas its accumulation can be either correlated 
with upregulation of ICAM-1 immunoreactivity in the vessels or associated with capillary 
closure (McLeod et al., 1995). 
In diabetic rodent models, along with the progression of DR, there is a 
cumulative and sustained increase in leukocyte adherence to the retinal vasculature – 
leukostasis (Miyamoto et al., 1999). This augment however may be linked to diabetes-
induced increases in ICAM-1 and integrins in endothelial cells and leukocytes, 
respectively, since ICAM-1 block or deletion of CD18 (ICAM-1 receptor subunit on 
leukocytes) seem to act as a preventive in diabetes-induced leukostasis (Miyamoto et 
al., 1999, Joussen et al., 2000, Barouch et al., 2004). 
In addition to inflammation-triggered circulatory leukocytes, retinal microglial 
cells – resident ocular macrophages – (Fischer et al., 2001) are also most likely to be 
involved in DR (Chen et al., 2002), being rapidly activated to release inflammatory 
cytokines such as TNF (Yang et al., 2009). On the other hand, studies in wild-type mice 
revealed that the treatment with the A2A adenosine receptor agonist resulted in 
marked decreases either in tumor necrosis factor (TNF) release or in hyperglycemia-
induced retinal apoptosis (Ibrahim et al., 2011). 
3.2. ROLE OF INFLAMMATION IN BLOOD RETINAL BARRIER 
ALTERATION 
Briefly, the blood-ocular barrier system is formed by two main barriers: the 
blood-aqueous barrier and the blood-retinal barrier (BRB). This barrier, particularly tight 
and restrictive, is a physiologic-type, because it regulates ion, protein, and water flux 
into and out of the retina. The BRB consists of inner, being formed of tight junctions 
between retinal capillary endothelial cells and outer components, and outer BRB which 
has tight junctions between retinal pigment epithelial cells. Furthermore, BRB is as 
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essential to maintaining the eye as a privileged site as it is indispensable for normal 
visual function; in fact it is exactly why alterations of the BRB play a crucial role in the 
development of retinal diseases. The 2 most frequent and relevant retinal diseases, 
diabetic retinopathy and age-related macular degeneration (AMD), are directly 
associated with alterations of the BRB. The first is initiated by an alteration of the inner 
BRB, whereas neovascular AMD is a result of an alteration of the outer BRB, being 
therefore the macular edema a direct result of alterations in the BRB (Cunha-Vaz et al., 
2010). 
Alteration of the inner blood retinal 
barrier (BRB) is the hallmark of diabetic 
retinopathy (Aveleira et al., 2010) (Figure 1.8). 
And, inflammation is one of the earlier events 
in diabetic retinopathy, which there is 
increased adhesion of leukocytes to the 
microvasculature, resulting in the loss of 
endothelial cells and breakdown of the blood-
retinal barrier (Yuuki et al., 2001, Joussen et 
al., 2001). Hence the major stages for BRB 
alteration are enumerated next: increased 
expression of adhesion molecules, such as 
ICAM1, VCAM1, P-Selectin, followed by 
leukocyte adhesion in the diabetic retina 
endothelium (McLeod et al., 1995, Adamis et 
al., 2008); next, release of inflammatory 
cytokines, vascular permeability factors, and 
growth cytokines, what culminates into 
modifications in adherens and tight junctional 
proteins (for example, VE-Cadherin, Occludin, ZO-1 and Claudin) and also infiltration by 
diapedesis of the leukocytes into the retina. Nonetheless all of these steps contribute to 
the Blood-Retinal Barrier breakdown. 
Figure 1.8 - Disruption of the Neurovascular Unit of 
the Retina by Diabetes (Antonetti et al., 2012). 
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Moreover, Yuuki et al., in animal models of diabetic retinopathy showed that 
the inhibition of leukocyte adhesion prevents the loss of pericytes and the formation of 
acellular capillaries, leading therefore to the suppression of the blood-retinal barrier 
breakdown. Another study also suggested a possible mechanism involving proteolytic 
degradation of VE-cadherin which could be possibly linked to diabetes contribution to 
BRB (Navaratma et al., 2001). 
These recently identified inflammatory risk factors not only serve as potential 
biomarkers, but also give insights into the development of potential molecular targets 
for treating diabetic retinopathy. 
4. ANTI-DIABETIC THERAPY 
4.1. EXISTING NON-INSULIN ANTI-DIABETIC THERAPY 
At the present time, to treat/control diabetes medicine relies on either the 
classic insulin therapy or on the non-insulin antidiabetic one, this is, metformin, 
sulphonylureas, meglitinides, thialidonediones, alpha-glucosidase inhibitors, amilin 
analogs, GLP-1 receptor agonists and DPP-IV inhibitors. These agents act in different 
sites of the organism to amelliorate insulin secretion and/or even its action. (Weiner, L. 
et al., 2010). 
4.1.1. INCRETINS 
In the last decade incretins have become object of attention due to its potential 
as a new type 2 Diabetes therapy. Nonetheless this concept was already known almost 
half a century ago, once it was observed that orally administered glucose stimulated a 
bigger insulin release then the same amount of the injected subtance (Eirick et al., 
1964). From this investigation two hormones, namely glucagon-like-peptide-1 (GLP-1) 
and glucose-dependent insulinotropic peptide (GIP), this is, incretin hormones were 
found responsible for the signal which led to gastrointestinal tract release of insulin 
whenever food was being consumed. 
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However it is now known that after being secreted by the gastrointestinal tract 
while food is eaten, incretin hormones bind to beta cells receptors in the pancreas, 
stimulating insulin secretion as a response to glucose absorption. (Ahrén, 2003). In 
healthy individuals it is also thought that incretin effect is responsible for approximately 
50 – 70% of insulinic-response to oral glucose, but a smaller secretion in type 2 Diabetes 
patients, might suggest that this could be linked to the disease pathogenesis (Nauck et 
al., 1986; VilsbØl et al., 2001). Drucker et al., later corroborated with this by showing 
that an increase in GLP-1 reduces hyperglycemia (Drucker, 2003). 
Consequently, and since GIP is inactive in type 2 Diabetes, a new incretin-like 
therapy based on GLP-1 endogenous levels was developed, in which two different 
approaches were pursued. The incretin mimetics, for example exenatide, and one 
Sitagliptin belongs to, hence the incretin secretors or DPP-IV inhibitors. 
4.1.1.1. INCRETIN MIMETICS 
Deacon et al, stated that these endogenous peptides (GLP-1 and GIP) were 
rapidly removed from circulation by DPP-IV enzyme and renal clearance. So it was 
necessary for the production of incretin-based therapies that these molecules had 
expand half-lifes and therefore exenatide and liraglutide were produced. 
4.1.1.1.1. EXENATIDE 
Exenatide was the first agent to be commercialized in 2005 and in the USA. It is 
a synthetic form of exenatide 4, a molecule originally isolated from the venon of the 
Heloderma suspectum. The exenatide however is not that analogous to human GLP-1, 
only sharing 53% of its molecular sequence. Despite the remaining structural similarity is 
enough for it to bind to GLP-1 receptor in order to mimic a significant number of 
glucoregulatory actions, not being able however to proceed as a DPP-IV susbstract. 
Exenatide decreases fasting and postprandial glucose concentrations through 
several mechanisms, also shared with GLP-1. In the pancreas, exenatide all together 
stimulates beta cells insulin secretion and suppresses alpha cells glucagon secretion 
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reducing for that reason, in a post-prandial state, hepatic glucose production. It also 
intervenes in gastric emptiness by slowing it down, promoting a satiety sensation, what 
eventually might lead to weight loss in overweight individuals (Linnebjerg et al., 2008). 
Nonetheless these events only need to occur in the presence of high circulatory glucose 
concentrations, in order to minimize hypoglycemic risk.  
In animal studies, exenatide can apparently promote pancreatic islets cells 
differentiation and inhibit beta cells apoptosis, altering the balance by increasing islets 
mass. Beta cells mass cannot be measured in humans through non-invasive procedures 
and in addition their function can only be determined in an indirect manner, for 
example, through pro-insulin:insulin ratio and beta cell function homeostasis evaluation 
(HOMA-b). These results seem to suggest that GLP-1 receptor agonist as well as DPP-IV 
inhibitors enhance beta cell function (Drucker, 2006). 
Finally, in contrast with exenatide and due to a higher homology between 
liraglutide and endogenous GLP-1, there is a decreased risk of antibody formation 
(Marre et al., 2009; Russell-Jones et al., 2009). Nonetheless a clinical relevance for the 
antibodies issue remains yet known for both agents. 
4.1.2. DPP-IV INHIBITORS 
DPP-IV, or Dipeptidyl-peptidase IV, Inhibitors, can often be known as gliptins, 
since they increase incretin hormones levels by inhibiting the enzyme responsible for 
their breakdown (DPP-IV). This results in higher endogenous GLP-1 half-life and levels. 
In Europe, 2007 and 2008 respectively, Sitagliptin and Vildagliptin were the first 
agents belonging to this class to be approved. Then Saxagliptin followed in 2009 and 
finally in April of the next year Alogliptin, in Japan. A couple of other molecules are still 
in trial stages, such as, Linagliptin and further DPP-IV inhibitors are also being developed. 
Their action mechanism involves a competitive and a reversible inhibition, 
about 90% of the plasmatic DPP-IV activity, with a duration period of 24 hours (Deacon 
and Holst, 2006). Although DPP-IV resistant incretin analogues (e.g. exenatide, 
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liraglutide) have the same biochemical target than the DPP-IV inhibitors, these last are 
only able to increase GLP-1 levels up to physiological values while the others can 
increase it by 6-10-fold that of the physiological ones found in the postprandial state 
(ElbrØnd et al., 2002, Drucker et al., 2008, Calara et al., 2005). 
In addition, among DPP-IV inhibitors glucoregulatory actions are included 
insulin secretion stimulation, glucagon secretion inhibition, on the whole improvement 
in beta cells function. In spite of this DPP-IV inhibitors seem to not mediate all 
endogenous GLP-1 glucoregulatory actions, having therefore little or no effect in gastric 
emptiness or satiety for that matter, what might be implied in their neutrality regarding 
the weight issue. DPP-IV inhibitors on other hand can be divided into two classes which 
are either related to their structural form or their excretory pathway (Nauck et al., 
2009). 
First, they are divided due to the presence or absence of the cyano-pirrolidine 
ring, since the ones who do possess it, namely Vildagliptin and Saxgliptine are less 
selective (not clinically relevant though) than the others who don’t, hence Sitagliptin, 
Alogliptin and Linagliptin. 
Second, Sitagliptin and Alogliptin remain almost inaltered when kidney-
excreted whereas Saxagliptin and Vildagliptin are metabolized respectively, as an active 
metabolite (in the kidney and liver) and an inactive one. 
As a final point, Linagliptin is the only DPP-IV inhibitor that could be mainly 
suggested to patients with renal insufficiency since it doesn’t have a known renal-
excreted pathway. 
5. DEMAND FOR NEW DRUGS 
Diabetes is a chronic disease that affects a still-rising number of people. 
Although the drugs available are initially efficient when trying to achieve the 
recommended glycaemic control, in a long term and without constant adjustments or a 
combination therapy it becomes difficult to accomplish this kind of management. 
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Above and beyond with the exception of TZD’s the available drugs have a 
reduced effect on Diabetes progression due to the continuous degradation in pancreatic 
beta cells function. Furthermore a higher risk of hypoglycemia and overweight 
associated to several therapies also represent huge difficulties for the optimal glycaemic 
control. 
More importantly it must be taken into consideration both the drug´s glycaemic 
reduction rate and the underlined mechanisms that led to this decrease. Subsequently 
new drugs beyond aiming for glycaemic control must be projected to control diabetes 
through yet unsolvable questions: better tolerance, lingering .efficiency and overall 
capacity to act on the actual cause of the disease. 
In a previous work from our laboratory, Gonçalves et al, showed that sitagliptin, 
prevents oxidative stress, inflammation and even apoptosis in retinal cells and exerts 
beneficial effects on the integrity of the blood-retinal barrier in an animal model of type 
2 diabetes (Gonçalves et al., 2012). In addition, it also demonstrated, in a model of type 
1 diabetes, that sitagliptin can inhibit blood-retinal barrier breakdown, leading to 
restored tight junctions organization, induced neuronal cells protection and enhanced 
retina inflammatory condition Nevertheless these studies seem as well to indicate that 
sitagliptin directly protects the retinal endothelial cells, but, until now, is not clear 
whether this drug could have a role in angiogenesis or vascular repair. 
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6. OBJECTIVES OF THIS THESIS 
Diabetes is a metabolic disease increasingly common, with an increasing 
prevalence worldwide. It is expected that 220 million people have diabetes and it is 
estimated that this number will doubled in the next 30 years. If not controlled, diabetes 
can lead to an increased risk of chronic complications including diabetic retinopathy. 
Chronic hyperglycemia leads to endothelial cell dysfunction resulting in loss of retinal 
pericytes, formation of acellular capillaries, increased vascular permeability and 
leukocyte adhesion 
The diabetes-induced vascular permeability appears to correlate with the 
disruption of the integrity of the tight junctions, which form a complex structure 
between endothelial cells, constituting the inner blood-retinal barrier. The chronic 
hyperglycaemia induces changes in the levels and distribution of proteins of tight 
junctions in the retinal vascular endothelium, which appears to directly contribute to 
increased vascular permeability. Diabetes induces metabolic and physiological 
abnormalities in the retina and it appears that inflammation plays a major role in the 
development of diabetic retinopathy. 
Since the microvascular complications are correlated with the severity and 
duration of hyperglycemia, it is highly desirable to find drugs that would permit an 
improvement in glycemic control and may also have an important role in delaying or 
preventing microvascular complications. 
Previous work from our laboratory showed that an inhibitor of dipeptidyl 
peptidase IV, sitagliptin, prevents oxidative stress, inflammation and apoptosis in retinal 
cells and exerts beneficial effects on the integrity of the blood-retinal barrier in an 
animal model of type 2 diabetes. In addition, it also showed that sitagliptin inhibits the 
breakdown of the blood-retinal barrier, so that tight junctions organization could be 
restored, inducing neuronal cells protection and enhancing the inflammatory condition 
of the retina in a model of type 1 diabetes. Nevertheless these studies seem to indicate 
that sitagliptin directly protects the endothelial cells of the retina. However, until now, is 
not clear whether this drug may have a role in angiogenesis or vascular repair. 
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For this work, we intend to use the primary cell cultures of bovine retinal 
endothelial cells (BREC) to evaluate the potential protective effect of sitagliptin in 
angiogenesis induced by a pro-inflammatory cytokine TNF (Wound-Healing, Proliferation 
and MTT assay and also PI staining). Finally, another objective is to assess the effect of 
sitagliptin on the ability of BREC to form tubular structures like vessels (Angiogenesis 
kit). 
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Quoting Erwin Chargaff – Austrian biochemist responsible for unraveling two 
rules that lead to the double-helix-DNA structure discovery – “Science is wonderfully 
equipped to answer the question 'How?' but it gets terribly confused when you ask the 
question 'Why?' !” 
Hence, throughout this section it is going to be briefly explained the “how” part 
by enumerating methods as well as materials and reagents used during this thesis. 
BIOLOGICAL ASSAYS 
A bioassay (i.e., biological assay) is a procedure for the determination of the 
concentration of a particular constituent of a mixture or a measurement of the effects of 
a substance on living organisms. Hence they can measure under controlled conditions 
the effects of a biologically active substance using an intermediate in vivo or in vitro 
tissue or cell model. 
1. BREC ISOLATION 
BREC were isolated as previously described (Fernandes et al., 2004). Briefly, 
BREC were isolated from retinal capillaries of fresh bovine eyes. Under sterile conditions, 
the retinas were separated from other ocular tissues, washed in Dulbecco’s Modified 
Eagle Medium (DMEM) (Introgen, Carlbad, CA) and fragments of the contaminating 
retinal pigment epithelium were then removed. 
Next the retinas were transferred to an enzyme solution containing 100 µg/ml 
Pronase (Roche, Mannheim, Germany), 500 µg/ml Collagenase type I (Introven, 
Carlsbad, CA, USA), 70 µg/ml DNase (Sigma-Aldrich, St. Louis, MO, USA) and incubated 
with agitation for about 20 minutes, at 37°C. After incubation, the retinal digest was 
passed through two nylon meshes, of 210 µm and 50 µm. The microvessels retained on 
top of the 50 µm nylon mesh were collected in DMEM by centrifugation. The fragments 
were resuspended in DMEM containing low glucose concentrations (5.5 mM), 
supplemented with 15% (v/v) Fetal Bovine Serum (FBS) (Introgen, Carlsbad, CA, USA), 20 
µg/ml Endothelial Growth Factors (ECGF) (Roche, Mannheim, Germany), 100 µg/ml 
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heparin and antibiotic/antimycotic solution (100 U/ml Penicillin, 100 µg/ml 
streptomycin, 0.25 µg/ml amphotericine B, Sigma-Aldrich, St. Louis, MO, USA). 
The cells were plated and grown on 50 µg/ml fibronectin-coated flasks, (Sigma-
Aldrich, St. Louis, MO, USA) in a humidified incubator, at 37°C, in an atmosphere with 
95% of air and 5% of CO2. BREC were divided between 7 and 10 days after isolation. 
BREC used in all experiences were from passages 3 to 6. 
1.1. SUBCULTURING 
After reaching confluency BRECs were subcultured. The DMEM medium was 
removed from culture flasks by aspiration and discarded. BREC were rinsed with 5 ml of 
warm sterile Phosphate Buffer Saline (PBS: Na2HPO4 10 mM, KH2PO4 1.8mM, NaCl 137 
mM, KCl 2.7 mM, pH 7.4), in order to remove traces of serum which would inhibit the 
action of the trypsin. BREC cells were treated with 3 ml of trypsin 0.25% (w/v) (Life 
Technologies Corporation, Carlsbad, CA, USA) and incubated at 37° C for approximately 
5 minutes. The tryspsinization process was monitored at an inverted microscope. DMEM 
medium was added to inhibit further tryptic activity and the cells were dispersed by 
repeated pipetting over the surface bearing the monolayer. The cell suspensions were 
then centrifuged at 1,000x g for 5 min and cell pellet was resuspended in DMEM 
medium and appropriate aliquots of cells were added to new 75 cm2 culture flasks. The 
confluency and morphology of BREC were examined every day under an inverted 
microscope. BREC were subcultured at a ratio of 1 to 3 in the conditions described 
above. 
1.2. FREEZING CELLS 
Some BREC were stored frozen as stocks in liquid nitrogen using DMEM 
medium containing 10% (v/v) DMSO. Some stocks were also frozen at -80 °C for short 
periods of time. Cells were harvested following the same protocol used for routine 
subculture.The cell pellet was resuspended in DMEM medium and 900µl were aliquot 
into each sterile vial containing 100µl of sterile DMSO. The cells were frozen at -80 °C 
prior to transfer to liquid nitrogen. 
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1.3. DEFROSTING CELLS 
The  BREC  were  frozen  in  1  ml  vials  that  were  stored  at  ‐80°  C  or  in  liquid 
nitrogen.  The  vial  content  was  thawed,  as  fast  as  possible,  in  37°C  water  bath  and 
transferred to 5 ml of prewarmed regular BREC culture medium. After centrifugation at 
1,000  x  g  for  5  minutes,  the  supernatant  was  removed  and  the  cell  pellet  was 
resuspended  in regular BREC culture medium and the cells were allowed to grow  in 75 
cm2  flasksat 37°C  in a humidified  incubator gassed with 5%  carbon dioxide  (CO2) and 
95% air. 
1.4. TRYPAN BLUE ASSAY 
The  trypan  blue  assay was  used  for  viability  cell  counting  before  plating  for 
subculturing or for treatments. Trypan blue  is an organic dye that  is excluded by  living 
cells  with  intact  plasma  membranes,  whereas  dead  or  dying  cells  with  the  plasma 
membrane  compromised  take up  that dye. The  viable  cells appear brilliant under  the 
microscope whereas  the dying  cells appear with a blue  color,  since  the  compromised 
membrane allow dye uptake. To check cell viability before plating, cells were trypsinized 
and  resuspended  in  regular BREC medium. Then 20 µl of  cell  suspension  and 20µl of 
trypan  blue  stain  were  mixed,  and  the  cells  counted  using  a  haemocytometer.  The 
percentage of viable cells and the cell density (number of cells per unit of volume) were 
calculated. 
Calculations 
The concentration of viable cells/ml was calculated considering the average of 
viable cells  for each counted  square  (VCs), and  their volume, plus  the volume used  in 
ressuspension: 
Concentration of Cell/ml =  VCୱ ୶ ௗ௜௟௨௧௜௢௡ ௙௔௖௧௢௥ଵ୶ଵ଴షర  
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2. IMMUNOCYTOCHEMISTRY AND CONFOCAL MICROSCOPY 
The evaluation of cellular distribution of the proteins in BREC was performed by 
immunocytochemistry. BREC culture were plated on fibronectin-coated cover slips. 
Twenty-four hours after plating, the medium was removed and the cells were washed 
with PBS and fixed in 4% (m/v) paraformaldehyde (PFA) for 10 minutes. Cells were then 
permeabilized for 10 minutes in 1% (v/v) Triton X-100 in PBS and blocked with 10 % 
normal goat serum for 20 min Primary antibodies (Table 2.1) were diluted in PBS 
containing 0.02% (m/v) of BSA and (PBS/BSA). The primary antibodies were then added, 
and the cells were incubated for 1 hour in a humid chamber at room temperature. 
After incubation, the cells were extensively washed with PBS/BSA (3 washes x 5 
min). Specimens were subsequently incubated with secondary antibodies produced in 
goat against mouse and rabbit immunoglobulins (IgG), conjugated with Alexa Fluor 568 
(1:400)or Alexa Fluor 488 (1:200) fluorochromes (Molecular Probes Inc. OR, USA) and 
stained with 4',6-diamidino-2-phenylindole (DAPI) for 1 hour at room temperature. The 
coverslips were washed before mounting with Glycergel Dako mounting medium (Dako, 
Carpinteria, CA, USA). Negative control conditions were processed and prepared in the 
same manner described above with the exception of the primary antibody incubation 
that were omitted. Cells were visualized and images acquired on a confocal microscope 
(LSM 710, Carl Zeiss, Gottingen, Germany). 
MARKERS DILUTION SUPPLIER 
Monoclonal Anti-Vimentin antibody produced in 
mouse 
1:400 
Sigma-Aldrich, St. Louis, MO, 
USA 
Polyclonal Rabbit Anti-Human 
Von Willebrand Factor 
1:400 Dako, Carpinteria, CA, USA 
Monoclonal Anti-CD11b Antibody produced in 
mouse 
1:100 
Serotec (Bio-Rad 
Laboratories, Inc, ) 
Monoclonal Anti-Glial Fibrillary Acidic Protein 
(GFAP) antibody produced in mouse 
1:500 
Sigma-Aldrich, St. Louis, MO, 
USA 
DAPI 1:500 
Life Technologies 
Corporation Carlsbad, CA, 
USA 
Table 2.1 – Primary antibodies used for the immunocytochemistry 
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3. BREC TREATMENT 
On the day of the treatment, regular BREC medium was replaced by DMEM 
medium (without ECGF and heparin) containing 5% FBS for 3 h. Then, BREC were non 
treated (only incubated in the medium of the treatments) or treated for 6 hwith: (a) 5 
ng/ml or 10 ng/ml TNF (R&D Systems, Minneapolis, MN, USA); (b) 100 nM or 100 µM 
DPP-4 inhibitorSitagliptin (Sigma-Aldrich, St. Louis, MO, USA) (c) TNF plus sitagliptin in 
the concentrations above mentioned. 
 
 
 
 
 
4. DPP-IV ENZYMATIC ASSAY 
To measure the activity of DPP-IV, a fluorometric assay was employed, using H-
Gly-Pro-AMC.HBr (BACHEM, Bubendorf, Switzerland). Gly-Pro-AMC is cleaved by DPP-IV 
to release the fluorescent aminomethylcoumarin (AMC). 
The reaction was initiated by the addition of the fluorogenic substrate to a final 
concentration of 50 µmol/l. The final reaction volume for each well was 150 µl. 
Liberation of AMC was monitored, using an excitation wavelength of 360 nm and an 
emission wavelength of 460 nm (microplate reader Synergy HT, BioTek, Winooski, VT, 
USA), every 5 min for a total of 60 min. 
Figure 2.2 - Timeline containing sequential events to be performed in this work 
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For comparison of DPP-IV activity between samples, data was plotted as 
Relative Fluorescence Units versus time for each sample. The time range over which the 
reaction was linear was determined. A trend line for these data points was obtained and 
the slopes determined. 
5. ANGIOGENESIS ASSAY 
In order to assess the capability of BREC to form tube-like structures the 
Angiogenesis Assay Kit (EMD Millipore Corporation, Billerica, MA, USA) was used 
according to the manufacturer’s protocol. Briefly, ECMatrix gel solution was thawed at 
4°C overnight, mixed with ECMatrix diluent buffer, and placed in a 96-well microplate at 
37°C for 1 hour to allow the matrix solution to solidify. BRECs were trypsinized and then 
seeded onto the surface of the polymerized matrigel (3×104 cells/well). After that, BREC 
were treated with TNF (5 and 10ng/ml), sitagliptin (100nM and 100µM) or both. After 6 
h, BREC were visualized and photographed under a phase-contrast microscope (Leica 
Microsystems (Model DFC350)). 
6. WOUND-HEALING ASSAY 
Nearly confluent cell monolayers were scraped using a sterile 200 µL 
micropipette tip. The medium and dislodged cells were aspirated, and plates were 
replenished with DMEM medium with 5% FBS for 3 hours. Treatment of BREC was 
performed as before described. 
Images on light microscope (100x magnification; Leica Microsystems, Model 
DFC350) were acquired before treatment (t0) and after treatment (t6)Cells present in 
the denuded area represent the migration ability of the cells. Results were reported as 
the percentage of wound healing using the equation: 
% Wound Healing = [1 − (wound length at t6 / mean wound length at t0)] × 
100, where t0 is the time immediately following wounding. 
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7. BrdU PROLIFERATION ASSAY 
BREC proliferation was measured using  Roche Cell Proliferation ELISA Kit 
(Roche Diagnostics Corp., Indianapolis, IN, USA), which measures the BrdU incorporation 
during DNA synthesis as the cells replicate. Replacement of the traditionally used [3H]-
thymidine with 5-bromo-2’-deoxyuridine (BrdU) as the pyrimidine analog for DNA 
incorporation in dividing cells allows the incorporated BrdU to be detected by 
colorimetric immunoassay.  
Briefly for this colorimetric assay BREC cells were plated at a density of 2x104 
cells per well (150 µl per well), in 96-wells culture plates 24h before treatment. Next, 
after replacing the cells in DMEM medium with 5% FBS for 3 hours, theywere treated 
with TNF (5 and 10ng/ml), Sitagliptin (100nM and 100µM) or both. Cells were incubated 
with BrdU labeling solution during the last 4 hours of treatment. The supernatants were 
discarded and the cells were then fixed in 200 μL/well of FixDenat solution for 30 min. 
The supernatant was again thoroughly removed and anti-BrdU-POD solution (100 
μL/well of 1:100 dilution) was added and incubated for 90 min at room temperature. 
The antibody was removed and the cells were washed in PBS and the substrate solution 
(TMB) was then added and incubated for 15 minutes. The absorbance of the developed 
color was measured at 370 nm (with reference measured at 492 nm) (microplate reader 
Synergy HT, BioTek, Winooski, VT, USA). The data of BrdU incorporation are presented 
as % of control. 
8. MTT METABOLIC ACTIVITY ASSAY 
MTT acronym for 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide 
is a yellow-colored substance added directly to the medium in the wells, which permits 
the evaluation of cell viability. Thus, in living cells MTT becomes reduced into an 
insoluble formazan – giving rise to a bluish purple color. BREC cells were plated at a 
density of 3x104 cells per well (150 µl per well), in 96-wells culture plates 24h before 
treatment. Next, after replacing the cells in DMEM medium with 5% FBS for 3 hours, 
they were treated with TNF (5 and 10ng/ml), sitagliptin (100nM and 100µM) or both. 
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After treatment, the medium was discarded and the cells were washed with KREBS 
solution. Then KREBS (50µl) with MTT at the final concentration of 0.5 mg.ml-1 was 
added. 
Then the plates were incubated for 4 hours at 37°C in the dark. The resulting 
purplish color crystals were later dissolved by adding 100 µl of acidic isopropanol (0.04 
M HCl in absolute isopropanol). To solubilize completely this heterogeneous solution, 
repetitive pipetting was required as well as room temperature (RT) plate stirring on an 
automatic shaker in the dark. The positive control condition was performed by 
incubating the cellswith 1mM H2O2 for 1 hour. 
The absorbance was measured at 570 nm (using 620 nm as the background 
wavelength), using a plate reader spectrophotometer. The percentage of absorbance for 
each treated sample was normalized to that of the control. 
9. PROPIDIUM IODIDE (PI) VIABILITY ASSAY 
For this colorimetric assay,BREC were plated on fibronectin-coated glass 
coverslips 24h before treatment. Subsequently cells were placed in DMEM medium with 
5% FBS for 3 hours and then treated as previously described. After treatment, cells were 
stained with 5µM of PI (Sigma-Aldrich Co ) for 10 minutes. After several washes in PBS, 
cells were fixed in 4% PFA and the nuclei staining was performed by incubation with 
DAPI (1µg.ml-1) for 10 min. The coverslips were washed before mounting with Glycergel 
Dako mounting medium (Dako, Carpinteria, CA, USA)The positive control condition was 
performed by incubating the cellswith 5mM H2O2 for 10 minutes. Images of the PI and 
DAPI staining were captured using the fluorescence microscope (Leica Microsystems, 
Model DFC350). 
10. SOFTWARE 
Image J 1.42n (Wayne Rasband, National Institute of Health, USA) was used for 
the quantification of the migration percentage from the control in the Angiogenesis 
assay. 
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11. STATISTIC ANALYSIS 
BREC were isolated as previously described (Fernandes et al., 2004). Briefly, 
BREC were isolated from retinal capillaries of fresh bovine eyes. Under sterile conditions, 
the retinas were separated from other ocular tissues, washed in Dulbecco’s Modified 
Eagle Medium (DMEM) (Introgen, Carlbad, CA) and fragments of the contaminating 
retinal pigment epithelium were then removed. 
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1. CHARACTERIZATION OF PRIMARY CULTURES OF BREC 
Retinal endothelial cells obtained from bovines were characterized. These cells 
have a spindle-fiber shape morphology characteristic of an endothelial cell origin and 
the typical phase microscopic image of BREC is shown in Figure 3.1A. In order to 
determine the purity of endothelial cell culture, the expression of vWf, GFAP, CD11b, 
vimentin proteins in BREC were analysed by immunocytochemistry. Strong staining was 
observerd following incubation with anti-vimentin and anti-vWf antibodies, indicating 
vWf (endothelial marker) and vimentin (cytoskeletal marker) expression in BREC (Figure 
3.1 B and C) while is not the case for GFAP (astrocyte marker) and CD11b (microglia 
marker) (Figure 3.1 D and E). Using DAPI (nuclear dye) staining, we identified more than 
95% of cells expressing vWf. This finding shows that primary cultures used in this study 
are almost of endothelial origin. 
 
 
 
 
 
Figure 3.1 - Characterization of bovine retinal endothelial cells (BREC). (A) Phase microscopic image of BREC; (B, 
C, D and E) Cells were fixed and stained with antibodies directed against respectively vimentin (red), vWf (green), 
GFAP (red) and CD11b (red), nuclei was counterstained with DAPI (blue) and imaged by confocal microscopy 
Magnification 400x. 
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2. SITAGLIPTIN DECREASES THE ACTIVITY OF DPP-IV IN BREC 
FOLLOWING EXPOSURE TO TNF 
To investigate the effect of Sitagliptin on DPP-IV its activity was evaluated in 
BREC previously exposed to TNF in the absence or presence of Sitagliptin. For this, a 
fluorescence enzymatic activity assay was performed, in which DPP-IV cleaves a 
substrate Gly-Pro-AMC that releases a fluoroforous – AMC. Thus, an increase in AMC 
fluorescence is proportional to DPP-IV activity. As a first approach, we treated BREC with 
increasing concentrations of Sitagliptin for 6 hours and then we measured the activity of 
DDP-IV. We observed an inhibition of DPP-IV activity in a concentration-dependent 
manner (data not shown). 
We have chosen for this study two concentrations of Sitagliptin, 100 nM and 100 
µM, which induce a significant decrease in DPP-IV activity, approximately about 70% 
(31.57% ± 1.12 % of control; P<0.001) and close to 90% (10.51 ± 0.82 % of control; 
P<0.001), respectively when compared to control (Figure 3.2). Interestingly enough, in 
BREC treatment alone with 5 ng/ml TNF and 10 ng/ml TNF also decreased, although less, 
DPP-IV activity roughly to 48% (51.91 ± 4.20 % of control; P<0.001) and to almost 62% 
(39.09 ± 4.92 % of control; P<0.001), respectively when compared to control (Figure 3.2). 
What seems to suggest some sort a relation between DPP-IV activity and TNF 
concentration. 
Furthermore, 5 ng/ml TNF combined with each concentration of Sitagliptin also 
decreased DPP-IV activity, hence 100 nM Sitagliptin (29.01 ± 1.68 % of control) and 100 
µM (12.97 ± 0.87 % of control) when compared to 5 ng/ml TNF addition alone. In 
contrast, 10 ng/ml TNF added in concomitance with 100 µM Sitagliptin reduced DPP-IV 
activity (11.64 ± 0.66) to a larger extent than lower concentrations of Sitagliptin (100 
nM) (28.42 ± 1.81) when compared to 10 ng/ml TNF treatment alone 
Finally Sitagliptin seems to decrease DPP-IV activity, when in the presence of 
TNF, to levels similar to those registered for the respective inhibition of DPP-IV induced 
by each concentration of Sitagliptin alone. 
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3. EFFECT OF SITAGLIPTIN IN ENDOTHELIAL FUNCTION 
FOLLOWING INFLAMMATION 
Recent data from our laboratory has shown that sitagliptin prevented the 
increase in blood-retinal barrier permeability induced by diabetes and exerted 
protective effects against inflammation and pro-apoptotic state in the retina of diabetic 
rats, by a mechanism independent of glycemia normalization (Gonçalves et al., 2012). In 
this work, to evaluate the potential role of DPP-IV activity in endothelial cells response 
to inflammation, neovasculatization, endothelial cell proliferation, migration and 
survival, in inflammation conditions were evaluated by using the DPP-IV inhibitor, 
Sitagliptin. 
To investigate whether inhibition of DPP-IV protects endothelial function 
following an inflammatory stimulus, endothelial cells ability to form tube-like structures 
was evaluated using an angiogenesis assay. 
Figure 3.2 - Sitagliptin decreases the activity in BREC treated with TNF. BREC were incubated with TNF (5 or 10 
ng/ml) in the absence or presence of sitagliptin (100 nM or 100 μM) for 6h. DPP-IV activity was determined using 
the fluorogenic substrate Gly-Pro-AMC. Data are presented as percentage of control and represent the mean ± 
SEM of triplicates from four independent experiments. ***P<0.001 vs. control; #P<0.05, ###P<0.001 vs. TNF 5 
ng/ml; δδδP<0.001 vs. TNF 10 ng/ml; ANOVA followed by Bonferroni’s post hoc test. 
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The results analyzed suggest that in control condition the formed tube-like 
structures seem quite organized. After 6 hours of treatment with 5 or 10 ng/ml TNF, a 
loss of endothelial cells organization in tubular structures was observed (Figure 3.3). 
Treatment with 100 nM sitagliptin in combination with 5 or 10 ng/ml TNF was able to 
prevent this effect (Figure 3.3). Similarly, treatment with 100 µM sitagliptin, was also 
able to prevent the tube-like structures disorganization, but on the other hand 
treatment with Sitagliptin 100 µM and TNF 10 ng/ml seems not to exert the same 
effects under inflammatory conditions, since the structures are more brittle and less 
arranged (Figure 3.3). 
 
 
Since our data above suggest that inhibition of DPP-IV may positively regulate 
endothelial cell function under inflammation, we next evaluated migration of 
endothelial cells, which is an important component of the cascade of events of the 
angiogenesis process. To evaluate endothelial cell migration, we performed a scratch-
wound assay, by evaluating migration of endothelial cells into the denuded area. 
Figure 3.3 – Effect of DDP-4 inhibition on angiogenesis upon TNF treatment. BREC were incubated with TNF (5 or 
10 ng/ml) in the absence or presence of sitagliptin (100 nM or 100 μM) for 6h. Representative images, from each 
condition, showing endothelial cells grown on matrigel matrix forming capillary network structures. Duplicates 
from one independent experiment. Magnification 100x.  
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By analyzing both images (Figure 3.4 A and B) we can observe that 5 ng/ml TNF 
can decrease BREC migration when compared to control from (32.74 ± 1.42 % from t0) to 
(23.31 ± 1.54 % from t0; P<0.05). More so the highest concentration used of TNF (10 
ng/ml) seems to impair to a larger extent and more significantly BREC migration from 
(32.74 ± 1.42 % from t0) to (19.10 ± 1.28 % from t0; P<0.001) when compared to control. 
Furthermore this impairment induced by both concentrations of TNF seems to be 
alleviated in the presence of 100 nM Sitagliptin, from (23.31 ± 1.54 % from t0; P<0.05) to 
(40.51 ± 1.62 % from t0; P<0.001) when compared to 5 ng/ml TNF alone and from (19.10 
± 1.28 % from t0; P<0.001) to (37.45 ± 1.45 % from t0; P<0.001) when compared to 10 
ng/ml TNF alone (Figure 3.4 A and B). 
In contrast the highest concentration of Sitagliptin used (100 µM) does not seem 
to protect BREC from 10 ng/ml TNF-induced impairment, but in co-treatment with 5 
ng/ml TNF a increase is registered from (23.31 ± 1.54 % from t0; P<0.05) to (32.88 ± 1.62 
% from t0; P<0.05) when compared to 5 ng/ml TNF alone (Figure 3.4 A and B). 
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After performing the wound-healing evaluation, a BrdU cell proliferation ELISA 
(colorimetric) KIT was used so that a correlation between both analyses could be 
established.  
The figure below shows that Sitagliptin does not seem to have any effect in 
BREC proliferation when compared to control. In contrast it appears that there is a 
tendency for increased BREC proliferation when they are treated with 100 nM Sitagliptin 
and both TNF concentrations (either 5 ng/ml or 10 ng/ml) when compared to control. 
Yet no alteration in proliferation induced by 100 µM Sitagliptin seem to exist when 5 
ng/ml TNF and 10 ng/ml TNF are present, when compared to each concentration of TNF 
alone (Figure 3.5). 
Nevertheless no statistical analysis was performed for this assay since it was 
made only one independent experiment. 
Figure 3.4 - Effect of sitagliptin on BREC migration upon TNF exposure. BREC were incubated with TNF (5 or 10 ng/ml) 
in the absence or presence of Sitagliptin (100 nM or 100 μM) for 6h. (A) Representative images, from each condition, 
showing endothelial cells migration compared to control and t0 hours. Duplicates from one independent experiment. 
Magnification 100x. (B) Data are presented as the percentage of migrated distance and represent the mean ± SEM of 
duplicates from one independent experiment. *p<0.05, ***p<0.001 vs. control; #p<0.05, ###p<0.001 vs. TNF 5 ng/ml; 
δδδp<0.001 vs. TNF 10 ng/ml; ANOVA followed by Bonferroni’s post hoc test. 
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After confirming that Sitagliptin exerts protective effects in BREC migration, 
proliferation and formation in tube-like structures, a cell viability assay was performed 
to support these results. 
Primary cultures of BREC were treated during a 6 hour period with two different 
concentrations of Sitagliptin (100nM or 100µM) and TNF (5 or 10 ng/ml). After this 
period the cell viability was evaluated by MTT colorimetric assay, in which this the 
yellow-colored MTT is reduced, by living cells mitochondrial dehydrogenases, to a sort of 
purplish-colored formazan precipitate. The absorption of dissolved formazan can be 
then correlated with living cells number, hence, being expressed by the percentage of 
cell viability in BREC cells. No significant cytotoxicity was registered when BREC were 
treated with TNF in the absence or presence of Sitagliptin (Figure 3.6).However, in the 
positive control condition, where the cells were exposed to hydrogen peroxide (H2O2) 
for 1 hour, an increased cytotoxicity was observed (45.43 ± 6.54 % of control; P <0.001) 
when compared to control (Figure 3.6). 
Figure 3.5 - Effect of sitagliptin on BREC proliferation upon exposure to TNF. BREC were incubated with TNF (5 or 
10 ng/ml) in the absence or presence of sitagliptin (100 nM or 100 μM) for 6h. Cell proliferation was assessed by 
BrdU incorporation. Data are presented as percentage of control and represent the mean ± SEM of triplicates 
from one independent experiment. 
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Theoretically, in the MTT assay, formazan dye color intensity is correlated with 
the number of viable cells. However, this assay is dependent of cellular metabolism to 
reduce formazan, so in order to confirm the obtained results, additional studies using 
the propidium iodide (PI) were performed. Since PI is excluded from live cells intact 
membrane and it is retained in dead cells, it can serve as a complementary assay to 
MTT. 
Furthermore, PI was added at the end of the co-treatments with two different 
concentrations of Sitagliptin (100nM e 100µM) and TNF (5 and 10 ng/ml). Qualitative 
evaluation of the images was performed by Fluorescence Microscopy. 
The representative images below show no cytotoxicity induced either by 
Sitagliptin and/or TNF. In addition, a positive control was performed, where the cells 
were exposed to 5mM hydrogen peroxide (H2O2) for ten minutes and increased 
cytotoxicity was observed due to total positive staining for PI. (Figure 3.7). 
Figure 3.6 – Effecct of sitagliptin on BREC viability after incubation with TNF. BREC were incubated with TNF (5 and 
10 ng/ml) and sitagliptin 100 nM or 100 μM for 6h. Cell viability was assessed by MTT assay. Data are presented as 
percentage of control and represent the mean ± SEM of triplicates from two independent experiments. ***p<0.001 
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Figure 3.7 - BREC were incubated with TNF (5 or 10 ng/ml) and/or sitagliptin (100 nM or 100 μM) for 6h. 
Representative images, from each condition, showing cell stained with PI. Duplicates from one independent 
experiment. Magnification 100x 
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Diabetic Retinopathy (DR) is one of the most common microvascular 
complications in diabetic patients and it is the major cause of blindness in the working-
age population of most developed countries. It is now widely accepted that the 
complications of diabetes, including DR, are related to elevation of the plasma glucose 
concentration (American Diabetes Association, Implications of the diabetes control and 
complications trial 2003; 23: S26-S27).It is also known that lowering blood glucose 
concentration significantly decreases the risk of DR development (Kowluru & Chan 
2007). Therefore, there is an urgent need to implement novel and more effective 
therapeutic strategies.  
Several reports have shown that a low-grade inflammation is implicated in the 
pathogenesis of DR (Kowluru et al., 2004). Elevated levels of proinflammatory 
cytokines have also been detected both in the vitreous of diabetic patients with DR 
(Kowluru et al., 2004) and in diabetic retinas (Lutty et al., 1997; Joussen et al., 2001). In 
fact, DR shares numerous characteristics of chronic inflammatory disease, such as, 
increased vascular permeability, edema, infiltration of inflammatory cells, presence of 
cytokines, tissue damage and neovascularization (Antonetti et al., 2006; Kowluru et al., 
2004). 
Recently, a new class of antihyperglycemic agents, in which is included 
Sitagliptin, have been used for the treatment of Type 2 Diabetes (T2D). Sitagliptin has 
been shown to improve glycemic control by enhancing the incretin levels of active 
incretin hormones, like GLP-1, and consequently increasing the insulin secretion levels 
in humans with T2D (Drucker et al., 2006). 
Moreover, it has also been shown that this DPP-IV inhibitor increases 
circulating progenitor endothelial cells in diabetic patients with T2D, which may have 
an important role in the repair of the damaged vessels (Fadini et al., 2010). Recently, 
our group has shown that administration of Sitagliptin to diabetic animals improved 
microvascular permeability and ameliorated the detrimental changes associated with 
retinal dysfunction. In fact, sitaglitin administration to T1DM and T2DM animal models 
reduced tissue inflammation, improving the functionality of the inner blood-retinal 
barrier. Nevertheless, the putative role of Sitagliptin in protecting retinal endothelial 
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cells under inflammatory stress conditions remains to clarify. In this study, we used 
primary cultures of bovine retinal endothelial cells to evaluate whether inhibition of 
DPP-4 by Sitagliptin regulates retinal endothelial cell response to inflammation induced 
by TNF. 
In both type 2 and type 1 diabetic patients and in STZ-induced diabetes in 
Wistar rats (after 1 month of diabetes induction), DPP-IV activity in serum was shown 
to be elevated (Bose et al., 2005; Gaspari et al., 2011). Sitagliptin treatment for two 
weeks was able to inhibit by 70% the activity of DPP-IV in the serum of diabetic 
animals, compared to untreated animals (A. Gonçalves, E. Leal, C. F. Ribeiro, F. Reis, A. 
F. Ambrósio and R. Fernandes. Sitagliptin prevents blood-retinal barrier breakdown, 
inflammation and neuronal cell death in the retina of type 1 diabetic rats (submitted 
for publication)). Other authors observed that DPP-IV activity in the plasma is 
increased 1 week after STZ injection and Sitagliptin treatment for a month led to a 
strong inhibition of DPP-IV activity and significantly increased levels of active plasma 
GLP-1 levels (Zhang et al., 2011). 
In a preliminary set of experiments we tested several concentrations of 
Sitagliptin, in order to choose one that inhibits by about 70% the activity of DPP-IV (in a 
similar way that was previously observed in diabetic animals) and another with the 
DPP-IV activity almost totally inhibited (90% of inhibition), corresponding to 100 nM 
and 100 µM Sitagliptin, respectively. When BREC were treated with 5 and 10 ng/ml 
TNF, we found an inhibition of about 50 and 60% in the activity of DPP-IV. The 
decreased DPP-IV activity could be related to a reduction in DPP-IV levels. In 
agreement with that, a recent study has recently described that proinflammatory 
cytokines such as TNF and IL-1b decrease the levels of DPP-IV protein and mRNA in 
microvascular cells (Takasawa et al., 2010). And, when BREC were co-treated with TNF 
and Sitagliptin, DPP-IV activity presented similar values to BREC treated only with 
Sitagliptin. However, further studies evaluating the protein levels of DPP-IV would be 
necessary to clarify whether unchanged activity is related or not to changes in the 
content of the DPP-IV protein. 
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Previous reports in the literature have shown that exogenous recombinant 
DPP-IV strongly regulated the migratory ability of T cells through (Endothelial Cells) EC 
(Ikushima et al., 2002). Lamalice et al., also claimed that endothelial cell migration is an 
essential component of angiogenesis that requires a tight regulation between 
proangiogenic and antiangiogenic factors. We found that TNF-induced inflammation 
impaired angiogenesis and that this was impeded in the presence of 100 nM 
Sitagliptin. This is in agreement with studies from Takasawa et al., which have shown 
that inhibition of CD26/DPP-IV enhances endothelial growth in vivo and in vitro, 
suggesting that inhibition of DPP-IV is directly associated with EC proliferation, 
migration and neovascularization in inflammatory settings (Takasawa et al., 2010).  
Moreover, the target vessels for angiogenic factors are the postcapillary 
venules and small terminal venules. These small-caliber vessels which consist of 
flattened endothelial cells that lie upon a basal lamina, are surrounded by an 
interrupted layer of pericytes and smooth muscle cells, and are invested in an 
extracellular matrix (Bar and Wolf, 1972; Ausprunk et al., 1974, Ausprunk and Folkman, 
1977; Sims et al., 1986; Philips et al., 1991). So, one of the first steps in the angiogenic 
response involves therefore the disruption of focal contacts between adjacent 
endothelial cells, pericytes, and smooth muscle cells (Bar and Wolf, 1972; Ausprunk et 
al., 1974, Ausprunk and Folkman, 1977; Sims et al., 1986; Philips et al., 1991). 
Suggesting that in our studies the brittleness in the tube-like structures induced by TNF 
could be related to an initial angiogenic response. In addition, Saison et al., proved that 
when 10 ng/ml of TNF was added to the fibrin gel assay it dramatically blocked 
sprouting, (Saison et al., 2008). We have also seen that this concentration of TNF does 
not seem to induce the formation of tube-like structures, since these last are so 
shortened and flimsy, that are almost non-existing. 
Saison et al., also demonstrated that delayed addition of TNF resulted in a 
quantitative reduction in the number of sprouts generated. Interestingly, however, 
when cultures were treated with a pulse of TNF for 2 days, followed by fresh medium, 
and the number of sprouts was counted 4 to 6 days later, there were more than twice 
as many sprouts by day 8 in TNF-pretreated than in control cultures never receiving 
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TNF. Thus, removal of TNF after 2 days led to robust sprouting that was more vigorous 
than in cultures that had never seen TNF. A pulse of TNF between days 2 and 4 also 
induced sprouting, however, a later pulse had no effect, likely because most of the 
sprouts had already been primed and initiated. This might suggest that our single TNF 
addition and the 6-hours- time-window could be too small, in order to observe TNF –
proangiogenic effect or perhaps the used TNF concentrations are low given the co-
treatment method employed. Nevertheless, more studies are needed to elucidate TNF 
angiogenic role in ECs tube-like structures formation and to confirm if Sitagliptin can in 
fact revert this impairment seen in BREC when exposed to an inflammatory stimulus. 
Furthermore, recent studies also referred that proliferation and migration of 
endothelial cells may play a crucial role in vascular self-repair in normal physiological 
as well as pathological conditions. More so, these cells are able to maintain their 
monolayer integrity via proliferation and migration of neighboring cells (Xiao et al, 
2013). In our studies we found that when BREC were treated with 5 and 10 ng/ml TNF 
in the presence of 100 nM Sitagliptin there was an increase in BREC proliferation 
(tendency) and migration, but when they were only exposed to TNF alone BREC 
migration significantly decreased. This might be in accordance with previous studies 
which showed that TNF blocks EC proliferation and migration in vitro (Mano-Hirano et 
al., 1987, Sato et al., 1986). 
However Park et al., demonstrated that Sitagliptin (50 to 200 µM) treatment 
inhibited PDGF-BB-induced cell proliferation in Rat Aortic Smooth Muscle Cells 
(RAoSMCs) and that the same treatment also inhibited TNF directed migration of 
RAoSMCs. Similar finding had been seen in the thymidine incorporation assay 
(proliferation). So it was verified that Sitagliptin treatment also inhibited TNF-directed 
migration of RAoSMCs in a dose-dependent manner from 50 to 200 µg/ml (Park et al, 
2012). Our findings show however that 100 nM Sitagliptin treatment seem to increase 
BREC migration and proliferation even in the presence of TNF. This increase could be 
related to the time gap between this investigation (24 hours) and ours (6 hours) as well 
as the cell type and Sitagliptin concentrations used for these experiments, which were 
different. This later is in fact in agreement to this research (Park et al, 2012) since they 
CHAPTER 4 
Discussion 
 
 
 
 
53 
also showed that migration with Sitagliptin 100 µM and TNF 10 ng/ml was decreased 
what is to some extent in accordance with our own studies. 
In regard to EC growth and proliferation, it appears that Sitagliptin effects 
depend on concentration as well as cell source. However further studies are required 
to clarify Sitagliptin protective action in BREC subjected to inflammatory stimulus. 
Moreover, in pathological conditions, such as inflammatory ones cell viability 
which is an indicator of a cell status, hence its ability for self-repair and self-preserve, 
might be impaired, so in order to assess the veracity of the premise we tested the 
experimental settings used previously to verify their effects on BREC cells viability.  
The results obtained either through MTT assay or by qualitative analysis of 
complementary assay – PI – reveal that the concentrations of Sitagliptin and TNF used 
are devoid of cytotoxicity. 
Aveleira et al, has observed that TNF (5 ng/ml) induced a significant decrease of 
cell viability after 24 h treatment, but no effect was observed after 6 h treatment 
(Aveleira et al., 2009). Using lower concentrations of TNF Chen et al., also 
demonstrated that treatment of HAECs with 2 ng/ml of TNF for 6 h did not result in 
cytotoxicity (Chen et al., 2002). Accordingly our results were partially consistent with 
those studies. Moreover and for higher concentrations of TNF (10 ng/ml) was verified 
that TNF treatment alone for 24 h significantly decreased (P < 0.01) BAEC proliferation 
by comparison with controls (Xiao et al., 2013).  
This might reinforce the fact that the chosen time-window of 6 hours could be 
too small in order to observe TNF-induced cytotoxic effects or that these effects seen 
so far are not due to an increase in cell death but just an impair in their function. All 
the same additional experiences are required to confirm that Sitagliptin exerts these 
cytoprotective effects in BREC when exposed to an inflammatory stimulus  
In conclusion, another BREC isolation and further studies are mandatory to 
confirm if this effect seen in DPP-IV inhibition can be directly associated to an improve 
in EC proliferation and migration. If so, this could imply that DPP-IV inhibitors, like 
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Sitagliptin, which are widely used in the treatment of diabetes, may be of potential use 
in treating diabetic vascular complications. 
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In this thesis we intended to evaluate the potential role of Sitagliptin in 
protecting the endothelial cells of the retina under inflammatory stress conditions. So 
in order to study the effect of Sitagliptin in the microvasculature of the retina, when an 
inflammatory state-TNF-induced is present, were used primary culture of Bovine 
Retinal Endothelial Cells (BREC). The fact that much is already known about the 
development and pathophysiology of the retinal microvasculature makes this capillary 
bed particularly well suited for in vitro studies (Bowman et al, 1982)  
Therefore a series of assays were performed on these cells together with 6 
hours in co-treatment with TNF and Sitagliptin. Hence endothelial cells ability to form 
tube-like structures, migrate and proliferate were analyzed and the results obtained 
suggest that Sitagliptin has protective and regenerative effects in these cells when 
exposed to an inflammatory-TNF-induced state. More so therapeutic benefits of 
Sitagliptin are consequently reinforced by these studies but TNF’s endothelial cells 
impairment ability was not yet fully understood. 
Nonetheless it is still important to refer that TNF role in angiogenesis continues 
to be highly controversial with numerous studies showing that it is either 
proangiogenic or antiangiogenic, with the preponderance of published studies 
suggesting that TNF blocks EC activation in vitro, but enhances angiogenesis in vivo 
(Patterson C et al., 1996, Frater-Schroder M et al., 1987, Mano-Hirano Y et al., 1987, 
Sato N et al, 1986, Leibovich SJ et al., 1987). 
Therefore to confirm the scientific veracity of our findings it is imperative to do 
another BREC cell culture isolation in which all the assays performed throughout this 
thesis will be redone and revised, comparing afterwards these future results with the 
former ones. 
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